A Historic Day in Shanghai
On July 13, 2026, Huashan Hospital affiliated with Fudan University — one of China's foremost neurosurgical centers — issued the world's first commercial prescription for an implantable brain-computer interface (BCI). On the same day, the hospital performed the world's first post-market commercial BCI implant surgery. In a single afternoon, a decade of laboratory research crossed the threshold into routine clinical care.
The Device: NEO Implantable BCI System
The NEO Hand Motor Function Compensation System was developed by Neuracle Technology (博睿康), a Beijing-based medical device company. On March 13, 2026 — just four months before this surgery — NEO received the world's first Class III medical device registration certificate for an invasive implantable brain-computer interface, issued by China's National Medical Products Administration.
Four months from regulatory approval to a fully reimbursed, fee-charging clinical procedure is an extraordinary pace by any global standard.
For a deeper overview of BCI therapy options now available in Shanghai, see our Complete 2026 Patient Guide to Brain-Computer Interface Therapy in Shanghai.
How it works: Micro-electrodes placed on the surface of the brain's motor cortex capture electrical signals generated when the patient intends to move their hand. An onboard processor decodes those signals — distinguishing "grasp" from "open fingers" — and transmits commands to an external compensation device that physically assists hand movement, effectively rebuilding the brain-to-limb signal pathway that spinal cord injury had severed.
The Patient: Mr. Xu's Journey
Mr. Xu is 37 years old. Ten years ago, a road traffic accident left him with a severe spinal cord injury at the C3–C6 vertebral level. The damage was extensive: both hands lost nearly all grasping function, and basic daily tasks — eating a meal, putting on a shirt, navigating a staircase — became impossible without assistance.
For years, Mr. Xu followed a rigorous rehabilitation program. He made meaningful early gains, but eventually reached the plateau that so many spinal cord injury patients know well: a point where conventional therapy can no longer produce further functional improvement, no matter how consistent the effort.
After a thorough multidisciplinary evaluation at Huashan Hospital — assessing neurological status, imaging findings, and alignment with the NEO system's approved indications — Mr. Xu was confirmed as an appropriate candidate. He became the world's first patient to receive a commercially implanted BCI device under a standard hospital prescription.
The Surgery: Minimally Invasive, Maximum Precision
The procedure was led by Dr. Chen Liang (陈亮), Deputy Director of Neurosurgery at Huashan Hospital's Neurosurgery Department. Dr. Chen is a Chief Physician and one of China's foremost experts in functional neurosurgery and brain-computer interface surgery, with extensive experience in minimally invasive cranial procedures for motor rehabilitation. The surgical approach was designed to minimize risk while maximizing signal quality.
- Access: A micro-bore opening of just a few millimeters in the skull — far smaller than conventional craniotomy.
- Placement: The titanium alloy main unit and electrode array were positioned in the epidural space, resting on the outer surface of the dura mater. The dura itself was not breached; no instruments entered brain tissue.
- Risk profile: By remaining entirely extradural, the approach substantially reduces the risk of intracranial infection, hemorrhage, and cerebrospinal fluid leakage compared to fully invasive cortical implants.
Intraoperative electrophysiological monitoring confirmed stable, high-quality signal acquisition throughout the procedure. Mr. Xu's vital signs remained stable, and the surgical team reported no complications.
Following wound healing, the system will be powered on and calibrated. A dedicated rehabilitation team will provide in-home training sessions, working toward the goals of independent grasping, controlled finger extension and flexion, and restored capacity for basic self-care.
Insurance Coverage: A First for China
The NEO BCI system has been included in the reimbursement scope of Hu Hui Bao (沪惠保), Shanghai's supplementary commercial health insurance program available to all Shanghai residents. This makes NEO the first implantable brain-computer interface device in China to be covered by any insurance scheme — a development that significantly reduces the financial barrier for patients with severe paralysis who might otherwise have no viable treatment pathway.
Why This Milestone Matters
The significance of July 13, 2026 extends well beyond one patient and one surgery.
For patients: Spinal cord injury affects more than 3.7 million people in China, with approximately 90,000 new cases each year. Until now, patients who reached the functional plateau after conventional rehabilitation had no further options. The commercial availability of BCI therapy — with insurance coverage — opens a new chapter. Future approved indications are expected to include post-stroke motor deficits and motor neuron disease, expanding the eligible population substantially. For patients exploring complementary neurological recovery options, our guide on Stem Cell Therapy in China for Neurological Disorders provides additional context.
For the industry: China has now completed the full commercial chain for invasive BCI technology: R&D → regulatory certification → hospital formulary listing → clinical surgery → insurance reimbursement. No other country has closed this loop for an implantable BCI device. China's domestic medical device sector has moved from follower to global frontrunner in this specific field.
For policy: The speed of this approval — coordinated across Shanghai's health authority, drug regulator, and medical insurance bureau — provides a replicable model for accelerating the clinical adoption of other frontier medical technologies across China.
What This Means for International Patients
Huashan Hospital's neurosurgery department is one of the most experienced in Asia, with deep expertise in complex cranial and spinal procedures. The department is led by Dr. Mao Ying (毛颍), Director and Chief Physician of Neurosurgery, and supported by distinguished faculty including Academician Zhou Liangfu (周良辅), a founding pioneer of modern Chinese neurosurgery. The world's first commercial BCI surgery was performed by Dr. Chen Liang (陈亮), Chief Physician and Deputy Director of Neurosurgery, whose specialization in functional neurosurgery and BCI implantation places him at the forefront of this emerging field. For patients with spinal conditions, Dr. Jiang Jianyuan (姜建元), Director of Spine Surgery, leads one of the country's most experienced spinal teams.
For international patients with spinal cord injury, stroke sequelae, or other conditions that may fall within BCI indications, this development represents a genuinely new option — one that is now available through standard hospital channels rather than experimental trial enrollment. Patients with stroke-related motor deficits may also wish to read our overview of Stroke & Cerebrovascular Disease care in Shanghai.
China Medical Concierge Shanghai (CMCS) works directly with Huashan Hospital's specialist teams. We can assist international patients with:
- Initial eligibility assessment and medical record review
- Coordination with the neurosurgery and rehabilitation teams
- Multidisciplinary consultation arrangement
- Translation, logistics, and in-hospital support throughout the treatment journey
If you or a family member is living with spinal cord injury or another condition affecting motor function, and you would like to understand whether BCI therapy may be appropriate, we are here to help.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 commenti